HCPlive (12/11, Derman) reports, “Cannabis-based medicinal products (CBMPs) are associated with improving anxiety, sleep quality, and health-related quality of life in patients with” AD/HD, “according to a new study.” The research found that “with the CBMP treatment, less patients had to take concomitant” AD/HD “medication, with a reduction of 38.46% in lisdexamfetamine, 15% in methylphenidate, and 14.29% in dexamfetamine.” The findings were published in Neuropsychopharmacology Reports.
Related Links:
— “Cannabis Treatment Linked to Improving Quality of Life in ADHD Patients,” Chelsie Derman, HCPLive, December 11, 2023